Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 1Meningioma 1

Interventions

Temozolomide 10Irinotecan 8Cyclophosphamide 7dinutuximab 5aldesleukin 4Interleukin-2 4Granulocyte-Macrophage Colony-Stimulating Factor 4sargramostim 3fludarabine 3Topotecan 3Melphalan 3Isotretinoin 3Filgrastim 3gallium Ga 68 dotatate 2Vincristine 2TPI-287 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Magnetic Resonance Spectroscopy 2Carboplatin 2venetoclax 1trametinib 1thymoglobulin 1talazoparib 1sonidegib 1silmitasertib 1plerixafor 1olaparib 1naxitamab 1lutetium Lu 177 dotatate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neuroblastoma × 64Cu-SARTATE × Clear all
NCT04023331 2025-09-16

67Cu-SARTATEâ„¢ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

Clarity Pharmaceuticals Ltd

Phase 1/2 Terminated
21 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡